Tumor invasion of muscular vessels predicts poor prognosis in patients with pancreatic ductal adenocarcinoma who have received neoadjuvant therapy and pancreaticoduodenectomy

American Journal of Surgical Pathology

Volumn 36, Issue 4, 2012, Pages 552-559

  Chatterjee, Deyali ^a   Rashid, Asif ^a   Wang, Hua ^a   Katz, Matthew H ^a   Wolff, Robert A ^a   Varadhachary, Gauri R ^a   Lee, Jeffrey E ^a   Pisters, Peter W ^a   Gomez, Henry F ^a   Abbruzzese, James L ^a   Fleming, Jason B ^a   Wang, Huamin ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

lymphovascular invasion; muscular vessel invasion; pancreatic cancer; prognosis; survival

Indexed keywords

ADJUVANT THERAPY; AGED; ARTICLE; CANCER INVASION; FEMALE; HUMAN; MALE; MIDDLE AGED; MORTALITY; PANCREAS; PANCREAS CARCINOMA; PANCREAS TUMOR; PANCREATICODUODENECTOMY; PATHOLOGY; PROGNOSIS; SURVIVAL RATE; UNITED STATES; VASCULAR SMOOTH MUSCLE; VASCULARIZATION;

AGED; CARCINOMA, PANCREATIC DUCTAL; FEMALE; HUMANS; MALE; MIDDLE AGED; MUSCLE, SMOOTH, VASCULAR; NEOADJUVANT THERAPY; NEOPLASM INVASIVENESS; PANCREAS; PANCREATIC NEOPLASMS; PANCREATICODUODENECTOMY; PROGNOSIS; SURVIVAL RATE; TEXAS;

EID: 84862808306     PISSN: 01475185     EISSN: 15320979     Source Type: Journal    
DOI: 10.1097/PAS.0b013e318240c1c0     Document Type: Article

References (27)

1. Badger SA, Brant JL, Jones C, et al. The role of surgery for pancreatic cancer: a 12-year review of patient outcome. Ulster Med J. 2010;79:70-75.
2. Barbier L, Turrini O, Gregoire E, et al. Pancreatic head resectable adenocarcinoma: preoperative chemoradiation improves local control but does not affect survival. HPB (Oxford). 2011;13:64-69.
3. Benassai G, Mastrorilli M, Quarto G, et al. Factors influencing survival after resection for ductal adenocarcinoma of the head of the pancreas. J Surg Oncol. 2000;73:212-218.
4. Cameron JL, Crist DW, Sitzmann JV, et al. Factors influencing survival after pancreaticoduodenectomy for pancreatic cancer. Am J Surg. 1991;161:120-124; discussion 124-125.
5. Chatterjee D, Katz MH, Rashid A, et al. Histologic grading the extent of residual carcinoma following neoadjuvant chemoradiation in pancreatic ductal adenocarcinoma: a predictor for patient outcome. Cancer. 2011. (In press).
6. Chen JW, Bhandari M, Astill DS, et al. Predicting patient survival after pancreaticoduodenectomy for malignancy: histopathological criteria based on perineural infiltration and lymphovascular invasion. HPB (Oxford). 2010;12:101-108.
7. Conlon KC, Klimstra DS, Brennan MF. Long-term survival after curative resection for pancreatic ductal adenocarcinoma. Clinicopathologic analysis of 5-year survivors. Ann Surg. 1996;223:273-279.
8. Edge S, Byrd D, Compton C, et al. AJCC Cancer Staging Manual. New York: Springer; 2010.
9. Estrella JS, Rashid A, Fleming JB, et al. Post-therapy pathologic stage and survival in patients with pancreatic ductal adenocarcinoma treated with neoadjuvant chemoradiation. Cancer. 2011. (In press).
10. Evans DB, Varadhachary GR, Crane CH, et al. Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. J Clin Oncol. 2008;26:3496-3502.
11. Gao CT, Li HK, Li Q. Factors influencing survival of patients with cancer of the pancreatic head after resection. Zhonghua Zhong Liu Za Zhi. 2009;31:554-557.
12. Garcea G, Dennison AR, Pattenden CJ, et al. Survival following curative resection for pancreatic ductal adenocarcinoma. A systematic review of the literature. JOP. 2008;9:99-132.
13. Gillen S, Schuster T, Meyer Zum Buschenfelde C, et al. Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages. PLoS Med. 2010;7:e1000267.
14. Guillem JG, Chessin DB, Cohen AM, et al. Long-term oncologic outcome following preoperative combined modality therapy and total mesorectal excision of locally advanced rectal cancer. Ann Surg. 2005;241:829-836.
15. Hatzaras I, George N, Muscarella P, et al. Predictors of survival in periampullary cancers following pancreaticoduodenectomy. Ann Surg Oncol. 2010;17:991-997.
16. Hernandez JM, Morton CA, Al-Saadi S, et al. The natural history of resected pancreatic cancer without adjuvant chemotherapy. Am Surg. 2010;76:480-485.
17. Huguet F, Orthuon A, Touboul E, et al. Pancreatic cancer. Cancer Radiother. 2010;14(Suppl 1):S94-S102.
18. Mansour JC, Tang L, Shah M, et al. Does graded histologic response after neoadjuvant chemotherapy predict survival for completely resected gastric cancer? Ann Surg Oncol. 2007;14: 3412-3418.
19. Mohammed RA, Martin SG, Gill MS, et al. Improved methods of detection of lymphovascular invasion demonstrate that it is the predominant method of vascular invasion in breast cancer and has important clinical consequences. Am J Surg Pathol. 2007;31: 1825-1833.
20. Mohammed RA, Martin SG, Mahmmod AM, et al. Objective assessment of lymphatic and blood vascular invasion in lymph nodenegative breast carcinoma: findings from a large case series with long-term follow-up. J Pathol. 2011;223:358-365.
21. Moral M, Fdez-Acenero MJ, Cuberes R, et al. Factors influencing prognosis after neo-adjuvant chemoradiation therapy for rectal carcinoma. Acta Chir Belg. 2009;109:345-351.
22. Regine WF, Abrams RA. Adjuvant therapy for pancreatic cancer: current status, future directions. Semin Oncol. 2006;33:S10-S13.
23. Rullier A, Laurent C, Vendrely V, et al. Impact of colloid response on survival after preoperative radiotherapy in locally advanced rectal carcinoma. Am J Surg Pathol. 2005;29:602-606.
24. Squadroni M, Fazio N. Chemotherapy in pancreatic adenocarcinoma. Eur Rev Med Pharmacol Sci. 2010;14:386-394.
25. Stocken DD, Buchler MW, Dervenis C, et al. Meta-analysis of randomised adjuvant therapy trials for pancreatic cancer. Br J Cancer. 2005;92:1372-1381.
26. Tepper J, Nardi G, Sutt H. Carcinoma of the pancreas: review of MGH experience from 1963 to 1973. Analysis of surgical failure and implications for radiation therapy. Cancer. 1976;37: 1519-1524.
27. Varadhachary GR, Wolff RA, Crane CH, et al. Preoperative gemcitabine and cisplatin followed by gemcitabine-based chemoradiation for resectable adenocarcinoma of the pancreatic head. J Clin Oncol. 2008;26:3487-3495.